中华男科学杂志

参考文献

[1]Homma Y,Gotoh M,Yokoyama O,et al.Outline of JUA clinical guidelines for begnign prostatic hyperplasia.Int J Urol,2011,18(11):741-756.

[2]AUA Practice Guidelines Committee.AUA guideline on management of benign prostatic hyperplasia(2003).J Urol,2003,170(1):530-547.

[3]Madersbacher S,Alivizatos G,Nordling J,et al.EAU 2004 guidelines on assessment,therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction(BPH guidelines).Eur Urol,2004,46(5):547-554.

[4]Agarwal A,Eryuzlu LN,Cartwright R,et al.What is the most bothersome lower urinary tract symptom?Individual and population-level perspectives for both men and women.Eur Urol,2014,65(6):1211-1217.

[5]Mangera A,Chapple C.Update summarising the conclusions of the international consultation on male lower urinary tract symptoms.World J Clin Urol,2015,14(2):1-1.

[6]那彦群.中国泌尿外科诊断治疗指南(2014版).北京:人民卫生出版社,2014.62-64.

[7]阀艳红,王学梅.双平面经直肠超声诊断良性前列腺增生的探讨.中华男科学杂志,2005,11(3):191-194.

[8]杨志刚,张飞,马旭东.前列腺增生致膀胱出口梗阻后逼尿肌功能改变对尿动力学参数的影响.现代泌尿外科杂志,2013,18(6):568-571.

[9]张亚大,卢子杰,顾晓箭,等.500例良性前列腺增生症中医证型与临床相关因素分析.南京中医药大学学报,2004,9(20):281-283.

[10]范洪力.良性前列腺增生症证候临床研究.中国医药指南,2008,12(6):401-402.

[11]张春和,李焱风,秦国政,等.540例良性前列腺增生症患者中医证候分布规律研究.中医杂志,2012,53(1):45-47.

[12]陈树山,赵刃.良性前列腺增生中医证型和用药规律分析.辽宁中医药大学学报,2012,14(9):137-139.

[13]韩旭,孙淑艳.良性前列腺增生常见中医证型分布规律及相关因素研究.现代中医临床,2014,21(6):16-18.

[14]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002.3.

[15]Djavan B,Marberger M.Meta-analysis on the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.Eur Urol,1999,36(1):1-13.

[16]Michel MC,Mehlburger L,Bressel HU,et al.Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms.Prostate Cancer Prostatic Dis,1998,1(6):332-335.

[17]胡雷,傅全胜,陈栋,等.选择性α-受体阻滞剂治疗良性前列腺增生症下尿路症状对男性射精功能影响的Meta分析.中山大学学报,2014,35(6):941-948.

[18]Ekman P.Maximum efficacy of finasteride is obtained within 6months and maintained over 6 years.Follow-up of the Scandinavian Open-extension Study.The Scandinavian Finasteride Study Group.Eur Urol,1998,33(3):312-317.

[19]Kaplan SA,Mc Connell JD,Roehrbom CG,et al.Medical Therapy of Prostatic Symptoms(MTOPS)Research Group.Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.J Urol,2006,175(1):217-220.

[20]Roehrborn CG,Siami P,Barkin J,et al.Comb AT Study Group.The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia:4-year results from the Comb AT study.Eur Urol,2010,57(1):123-131.

[21]Nickel JC,Gilling P,Tammela TL,et al.Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia:The enlarged prostate international comparator study.BJU Int,2011,108(3):388-394.

[22]Issa MM,Runken MC,Grogg AL,et al.A large retrospective analysis of acute urinary retention and prostate-related surgery in BPHpatients treated with 5-alpha reductase inhibitors Dutasteride versus finasteride.Am J Managed Care,2007,13(Suppl 1):S10-S16.

[23]Fenter TC,Davis EA,Shah MB,et al.Dutasteride vs finasteride:Assessment of differences in acute urinary retenion rates and surgical risk outcomes in an elderly population aged>or=65 years.Am J Managed Care,2008,14(5 suppl 2):S154-S159.

[24]Clark RV,Hermann DJ,Cunningham GR,et al.Marked suppression of dihydrotestosterone in men with benign prostatic hrperplasia by dutasterirle.A dual 5 alpha-reductase inhibitor.JClin Endocrinol Metab,2004,89(5):2179-2184.

[25]Yamada S,Kuraoka S,Osano A,et al.Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.Int Neurourol J,2012,16(3):107-115.

[26]Abrams P,Kaplan S,De Koning Gans HJ,et al.Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.J Urol,2006,175(2):999-1004.

[27]Oelke M,Bachmann A,Descazeaud A,et al.EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.Eur Urol,2013,64(1):118-140.

[28]詹绪新,商学军,黄宇烽.锯叶棕果实提取物在治疗前列腺疾病中的应用.中华男科学杂志,2015,21(9):841-846.

[29]Ilic D,Misso M.Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer:A systematic review.Maturitas,2012,72(4):269-276

[30]韩伟,张喜庄,杨永军,等.单用宁泌泰胶囊治疗BPH疗效观察.临床泌尿外科杂志,2012,27(11):853-854.

[31]戚益江,王逸民.前列倍喜胶囊联合非那雄胺治疗良性前列腺增生症疗效观察.浙江中西医结合杂志,2011,21(9):630-631.

[32]张雪松,成生海.翁沥通胶囊联合西药治疗良性前列腺增生症48例.中国实验方剂学杂志,2012,18(23):325-327.

[33]魏强,鲍一歌.经尿道前列腺电切术仍是前列腺增生症治疗的首选方法.现代泌尿外科杂志,2012,17(3):294-298.

[34]杜元灏,李晶,孙冬玮.中国现代针灸病谱的研究.中国针灸,2007,27(5):376.

[35]陈元武,杜元灏,熊俊.针灸与西药治疗前列腺增生症疗效比较的系统评价.中华中医药杂志,2010,25(6):902-906.

[36]琚保军,牛琳琳.中药经直肠给药治疗良性前列腺增生疗效及安全性评价.新中医.2014,46(8):71-73.

[37]陈寅,郑珉,汤群晖,中药灌肠治疗前列腺电切术后膀胱痉挛痛的疗效分析.中华中医药学刊,2010,28(8):1691-1692.

[38]贾民,张晓宇,胡胜平,等.中药敷脐联合电针治疗经尿道前列腺电切术后膀胱过度活动症临床观察.中国中医急症,2014,23(9):1719-1722.

[39]张春和,秦国政,陈天波,等.前列冲剂治疗前列腺增生症膀胱逼尿肌功能受损的临床研究.云南中医学院学报,2008,31(2):37-42.